

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

REQUEST FOR ACTION

Subject: Regental Action Under the State of Michigan Conflict of Interest Statute

Action Requested: Authorize Execution of Investment Agreements Under the MINTS Program for EVOQ Therapeutics LLC

Background

In December 2011, the Board of Regents approved guidelines for the MINTS ("Michigan Investment in New Technology Startup") program.

The proposed investment agreements (the "Agreements") fall under the State of Michigan Conflict of Interest Statute because the listed Interested Individuals are employees of the University and have sufficient pecuniary interest in the Agreements as partial owners of the company, and/or undertake a board role. The law permits such an agreement provided it is disclosed to the executive officers and approved in advance by a 2/3 vote of the Board of Regents.

No use of University services or facilities, nor any assignment of University employees, is obligated or contemplated under the Agreements.

If the transaction proceeds, the parties to the Agreements would include the University and the entity listed below, and the University would receive an equity interest in the entity in return for its investment(s). The Agreements would reflect typical venture capital investing documentation.

The Investment Office is seeking approval for financing agreements up to a total of \$5 million in potential investments (through one or more rounds of financing) under MINTS for the below-listed startup. It is understood that, upon approval of this item, MINTS will have no obligation to enter into the Agreements or proceed with any investment in the company.

EVOQ Therapeutics LLC, founded in 2016, is a life sciences company which is developing a novel drug delivery mechanism using HDL nano-discs with applications in autoimmune and cancer therapies.

Interested Individuals:

James Moon, PhD
Professor of Pharmaceutical Sciences, and Professor of Biomedical Engineering
College of Pharmacy, College of Engineering

Anna Schwendeman, PhD
Professor of Pharmaceutical Sciences; Faculty Associate in the Interdepartmental Program in
Medicinal Chemistry
College of Pharmacy

We believe state law requirements have been met with the disclosure of the interest and formal appointment arrangements with the University of Michigan.

We recommend that the Board of Regents authorize execution of agreements between the University of Michigan and EVOQ Therapeutics LLC, as set forth above.

Respectfully submitted,



Geoffrey S. Chatas
Executive Vice President
and Chief Financial Officer